跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
VITRAKVI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
VITRAKVI
Authorized
STANDARD
VITRAKVI
Bayer Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
7f465ab1d14cb93e
Company
Bayer Inc
Type
Standard
Approval Details
Approval Id
7f465ab1d14cb93e
Drug Approval Canada Name
VITRAKVI
Product Name
VITRAKVI
Status
Marketed
Status Date
2019-09-04
Original Market Date
2019-09-04
Din
02490331
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EX12 LAROTRECTINIB
Atc Name
l 01 ex 12
Aig Number
0161630003
Company Name
Bayer Inc
Company Address
2920 Matheson Blvd East, Mississauga, Ontario, Canada, L4W 5R6
Active Ingredients
LAROTRECTINIB (LAROTRECTINIB SULFATE)
20 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
7f465ab1d14cb93e
Type
Standard
Back to Health Canada Approvals